Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites.
Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites.
复制标题
DOI:
10.2967/jnumed.116.174169
复制
发表时间:
2016-12
期刊:
影响因子:
--
通讯作者:
Beyer T
中科院分区:
文献类型:
--
作者:
Fendler WP;Czernin J;Herrmann K;Beyer T
Information has been collected from positron emission tomography/magnetic resonance imaging (PET/MRI) operational sites to identify its present and future applications. This may help to focus discussions on common interests of the PET/MRI community. A web-based survey of PET/MRI users was conducted from June to October 2015. The survey was composed of 26 questions related to (A) the PET/MRI center, (B) present utilization and imaging protocols and (C) perspectives on key applications. Responses were collected from 39 international sites that operated PET/MRI for a median of 30 months (range, 2 to 62 months). Most installations were located in public institutions with an academic focus (n=26, 67%). Systems were primarily operated by Nuclear Medicine Departments (n=13, 33%), jointly by Nuclear Medicine and Radiology (n=11, 28%), and Radiology only (n=10, 26%). PET/MRI operation was equally focused on clinic routine and research (47% vs. 45% of sites respectively). Sites reported a strong focus on oncology (76% of research and 88% of clinical applications). Other applications included neurology (9% clinical, 12% research) and cardiology (3% clinical, 6% research). Perceived superiority over positron emission tomography/computed tomography (PET/CT) was identified as the strongest driver for clinical adoption. Over half the operators expect PET/MRI to excel in clinical routine within three to five years. Emerging key applications for future PET/MRI use were cardiovascular disease and imaging of inflammation. An international survey of early PET/MR adopters reveals a mixed utilization of this combined imaging modality with a focus on oncology. The future of PET/MRI is seen in expanded application for oncology, neurology, but also cardiovascular disease and inflammation.
登录
查看更多内容
影响因子:
3.1
作者:
Bailey, D. L.;Antoch, G.;Bartenstein, P.;Barthel, H.;Beer, A. J.;Bisdas, S.;Bluemke, D. A.;Boellaard, R.;Claussen, C. D.;Franzius, C.;Hacker, M.;Hricak, H.;la Fougere, C.;Gueckel, B.;Nekolla, S. G.;Pichler, B. J.;Purz, S.;Quick, H. H.;Sabri, O.;Sattler, B.;Schaefer, J.;Schmidt, H.;van den Hoff, J.;Voss, S.;Weber, W.;Wehrl, H. F.;Beyer, T.
通讯作者:
Beyer, T.
影响因子:
3.5
作者:
Zaidi H;Ojha N;Morich M;Griesmer J;Hu Z;Maniawski P;Ratib O;Izquierdo-Garcia D;Fayad ZA;Shao L
通讯作者:
Shao L
影响因子:
3.5
作者:
Shao, YP;Cherry, SR;Marsden, PK
通讯作者:
Marsden, PK
影响因子:
19.7
作者:
Schlemmer, Heinz-Peter W.;Pichler, Bernd J.;Claussen, Claus D.
通讯作者:
Claussen, Claus D.
影响因子:
9.3
作者:
Delso, Gaspar;Fuerst, Sebastian;Ziegler, Sibylle I.
通讯作者:
Ziegler, Sibylle I.